April 19, 2012
Ono Pharmaceutical announced on April 17 that its investigational treatment for multiple sclerosis (MS) ONO-4641 demonstrated efficacy for the reduction of lesions in the global PII DreaMS study conducted in 11 countries including Japan, the US, and Europe, and met...read more